10 Best Small-Cap Value Stocks to Invest In Now
The slide in AI stocks is prompting investors to explore beyond the market's leading companies.
Precigen Inc. (PGEN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Patient Capital Management Samantha Mclemore | 17,950,104 | $153,652,894 | -6% | 4.88% |
| 2. | Iridian Asset Management David Cohen And Harold Levy | 3,064,571 | $26,232,728 | -24% | 9.54% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,335,271 | $19,989,920 | +31% | 0.01% |
| 4. | Renaissance Technologies Jim Simons | 639,500 | $5,474,120 | +6% | 0.01% |
| 5. | 168,900 | $1,445,784 | -55% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.23 | 3,411 | $24,661.53 | 309,187 | 2026-08-21 | Filing | |
| $3.40 | 2,000 | $6,800.00 | 405,959 | 2025-09-26 | Filing | |
| $3.58 | 6,000 | $21,480.00 | 65,031 | 2025-09-29 | Filing | |
| $3.42 | 2,932 | $10,027.44 | 468,626 | 2025-09-26 | Filing | |
| $3.62 | 8,284 | $29,988.08 | 465,694 | 2025-09-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.44 | 185,000 | $1,376,400.00 | 17,100 | 2026-08-26 | Filing | |
| $7.50 | 15,342 | $115,065.00 | 468,865 | 2026-08-25 | Filing | |
| $7.50 | 34,658 | $259,935.00 | 465,012 | 2026-08-21 | Filing | |
| $7.50 | 79,166 | $593,745.00 | 141,992 | 2026-08-25 | Filing | |
| $6.86 | 32,739 | $224,589.54 | 465,012 | 2026-08-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,280,537 | $147,921,397 | 0% | |
| 2. | 10,719,117 | $91,755,642 | 0% | |
| 3. | 8,011,028 | $68,574,400 | 0% | |
| 4. | 5,087,896 | $43,559,198 | 0% | |
| 5. | 4,131,722 | $35,367,544 | 0% |
News See All
10 Best Biotech Stocks Under $10 to Buy
Biotechnology stocks have delivered strong gains in 2026, supported by encouraging clinical trial results, regulatory approvals, and growth in drug sales.
Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis
Patient Capital Management, based in Baltimore, released its third-quarter 2026 investor letter for the “Patient Opportunity Equity Strategy”. The letter can be downloaded here.
Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?
Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS.
10 Stocks Paying Off Big Time
Ten stocks kicked off the trading week with strong gains, bucking a lackluster performance on the broader market, thanks to a flurry of positive industry news that spilled over to their stocks.
10 Penny Stocks With Explosive Growth Potential
In this article, we will discuss the 10 Penny Stocks With Explosive Growth Potential.
10 Best Penny Stocks That Could Skyrocket in 2026
In this article, we will look at the 10 Best Penny Stocks That Could Skyrocket in 2026.
10 Best Penny Stocks to Buy for Long Term
In this article, we will look at the 10 Best Penny Stocks to Buy for Long Term.
Precigen, Inc. (NASDAQ:PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (NASDAQ:PGEN) Q1 2026 Earnings Call Transcript May 13, 2026Precigen, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.03.
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is PGEN a good stock to buy? We came across a bullish thesis on Precigen, Inc. on Valueinvestorsclub.com by coalone. In this article, we will summarize the bulls’ thesis on PGEN.
Hedge Fund Resource Center